info@news-matic.com

Privacy Terms Contact
AirHelp travel assistance ad
ads-image
ads-image
details

Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

Seven-year data show lorlatinib keeps ALK+ lung cancer controlled, with durable brain protection, stable safety, and clues to early resistance.

In This Category

details
Russia pulls team from gymnastics World Cup event
details
Serena Williams to face Joint in Wimbledon return
details
Malo Gusto on playing alongside France and Chelsea
details
Fifa World Cup: sorrowful South Korea erect Mexico
details
ads-image
ads-image

ADVERTISEMENT

Ad 1
Ad 2
Ad 3

Get in Touch

info@news-matic.com

Latest Post

Quick Links

Newsletter

Terms of use Privacy policy Cookies Accessibility help Advertise with us Contact us Sitemap

ADVERTISEMENT

Ad 1
Ad 2
Ad 3

2026 Copyright © News-Matic.com. All Rights Reserved

Cookie Consent + Tracking